Those findings, supported by biological evidence from genetically engineered mouse models, suggest KRAS alterations drive PDAC initiation while subsequent mutations in CDKN2A and other tumor suppressors are rate-limiting for tumor progression [181]. The gene discussed is CDKN2A; the disease is neoplasm.